免疫检查点抑制剂在尿路上皮癌一线治疗中的应用
本文总结了三项近期随机试验,评估免疫检查点抑制剂单药或联合化疗用于既往未治疗的转移性尿路上皮癌患者。结果显示免疫单药并不优于化疗,化疗联合免疫可能显示获益信号但不足以改变临床实践。
要点
- 免疫检查点抑制剂单药一线治疗不优于化疗。
- 化疗联合免疫治疗显示可能的疗效信号。
- 联合治疗获益幅度不足以改变现有推荐。
核心结论
- 免疫检查点抑制剂单药一线治疗不优于化疗。
- 化疗联合免疫治疗显示可能获益信号但不足以改变实践。
研究设计与样本
- 总结三项近期随机试验,纳入既往未治疗的转移性膀胱癌患者。
主要发现
- 免疫单药不优于化疗。
- 化疗联合免疫显示可能疗效信号但不足以改变推荐。
临床怎么用
- PD-L1阳性且顺铂不耐受的转移性尿路上皮癌一线仍可选免疫检查点抑制剂单药。
- 化疗联合免疫证据尚不足以改变现有治疗推荐。
局限性
- 支持免疫单药的数据基于两项单臂试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors are the standard-of-care front-line treatment option for PD-L1-positive, cisplatin-ineligible metastatic urothelial carcinoma. The data supporting this are based on two single-arm trials. Randomised trials to confirm these findings and test new combinations have recently been performed. It was hoped that these trials would clarify some of the previous uncertainties. In this report we summarise the findings from these trials and perform a combined analysis. The results show that immune checkpoint inhibitor monotherapy is not superior to chemotherapy as things currently stand. The chemoimmunotherapy combination shows a probable efficacy signal, but this appears to be insufficient to change practice. PATIENT SUMMARY: In this report, we summarise the outcomes of three recent trials that investigated immunotherapy (IMT) on its own and combined with chemotherapy (CT) for patients with metastatic bladder cancer who had not previously received any treatment. We show that IMT on its own is not better than CT for these patients. There is a sign that combined CT and IMT probably has a benefit, but it does not seem to be large enough to justify a change in treatment recommendations.
引用
- Szabados B, Prendergast A, Jackson-Spence F, et al. Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. Eur Urol Oncol. 2021. PMID: 33811019. doi:10.1016/j.euo.2021.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。